Research Topics
| Stefan D AnkerSummaryAffiliation: Imperial College Country: UK Publications
| Collaborators
|
Detail Information
Publications
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACHStefan D Anker
Applied Cachexia Research, Department of Cardiology, Charite, Campus Virchow Klinikum, Berlin, Germany
Int J Cardiol 86:123-30. 2002..High dose anti-TNF therapy may not be useful in CHF patients, but the situation in lower doses and in patients with documented inflammatory/metabolic problems or in cardiac cachexia has not yet been adequately assessed...- Inflammatory mediators in chronic heart failure: an overviewStefan D Anker
Department of Clinical Cardiology, Imperial College School of Medicine, National Heart and Lung Institute, London, UK
Heart 90:464-70. 2004 - Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational studyStefan D Anker
Applied Cachexia Research, Department of Cardiology, Charite, Campus Virchow Klinikum, Berlin, Germany
Lancet 361:1077-83. 2003..We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors... - Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patientsStefan D Anker
Applied Cachexia Research, Department of Cardiology, Charite Campus Virchow Klinikum, Berlin, Germany
Int J Cardiol 112:234-42. 2006..Treatment with statins may lead to a lower mortality in CHF, independent of cholesterol levels, CHF etiology and clinical status... - Cardiac cachexiaStefan D Anker
Department of Clinical Cardiology National Heart and Lung Institute, Imperial College London, UK
Ann Med 36:518-29. 2004..The available evidence suggests that cardiac cachexia is a multifactorial neuroendocrine and metabolic disorder with a poor prognosis. A complex imbalance of different body systems may cause the development of body wasting... - Effect of anemia on exercise tolerance in chronic heart failure in menPaul R Kalra
Clinical Cardiology, National Heart and Lung Institute, London, United Kingdom
Am J Cardiol 91:888-91. 2003 - Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesityConstantinos H Davos
Department of Cardiac Medicine, National Heart and Lung Institute, London, United Kingdom
J Card Fail 9:29-35. 2003..01 [0.98-1.05] and diagnosis (1.56 [0.78-3.11]) was not a predictor of survival. CONCLUSION: In patients with chronic heart failure, increasing BMI is not an adverse prognostic feature. Thinner patients appear to have a poorer prognosis... - Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failureStephan von Haehling
Applied Cachexia Research, Department of Cardiology, Charité Medical School Campus Virchow Klinikum, 13353 Berlin, Germany
Eur J Heart Fail 12:484-91. 2010..Adrenomedullin (ADM) is a vasodilatory peptide. Its plasma levels or its precursors have not been evaluated in large populations of patients with chronic heart failure (CHF). We sought to explore mid-regional proADM (MR-proADM)... - Cellular endotoxin desensitization in patients with severe chronic heart failureRakesh Sharma
Clinical Cardiology, NHLI, Imperial College School of Medicine, London, UK
Eur J Heart Fail 7:865-8. 2005..Production of IL-1RA is not affected. This resembles a picture indicative of LPS desensitization occurring in patients with severe CHF... - Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survivalSabine Genth-Zotz
Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
Int J Cardiol 96:397-401. 2004..We hypothesised that circulating Hsp70 levels are elevated in patients with CHF, more so in cachechtic patients, and that Hsp70 levels would relate to mortality... - The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failureStephan von Haehling
Department of Clinical Cardiology, National Heart and Lung Institute, London SW3 6LY, UK
Int J Cardiol 90:197-204. 2003..Elevated plasma levels of tumour necrosis factor-alpha (TNF-alpha) are present in patients with advanced chronic heart failure (CHF). However, the relationship between age and the immune response in CHF is unknown... - Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart diseaseRakesh Sharma
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
Am J Cardiol 92:188-93. 2003..Congenital heart disease in adults may be amenable to novel anti-inflammatory therapies in selected patients... - Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic stagingStefan D Anker
Applied Cachexia Research Unit, Charite, Campus Virchow Klinikum, Berlin, Germany
Circulation 107:1991-7. 2003..Serum uric acid (UA) could be a valid prognostic marker and useful for metabolic, hemodynamic, and functional (MFH) staging in chronic heart failure (CHF)... - Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteinsRakesh Sharma
Clinical Cardiology, NHLI, Imperial College School of Medicine, Dovehouse Street, SW3 6LY, London, UK
Eur J Heart Fail 7:479-84. 2005..CONCLUSIONS: Serum lipoproteins may play an important role in regulating LPS bioactivity in CHF. Very low LPS activity, at levels seen in vivo in CHF, can induce significant TNF-alpha production ex vivo... - Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure studyFriedrich Koehler
Department of Cardiology and Angiology and Center for Cardiovascular Telemedicine, Charite Universitatsmedizin Berlin, Campus Mitte, Berlin, Germany
Circulation 123:1873-80. 2011..This study was designed to determine whether physician-led remote telemedical management (RTM) compared with usual care would result in reduced mortality in ambulatory patients with chronic heart failure (HF)... - Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptorsStephan von Haehling
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
Am J Cardiol 95:885-9. 2005..This study demonstrated that noradrenaline and isoproterenol inhibit TNF-alpha production in patients with CHF in ex vivo whole blood in a dose-dependent fashion. The beta-blocker bisoprolol abolishes this effect... - Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trialRakesh Sharma
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London SW3 6LY, UK
Eur Heart J 25:1021-8. 2004..2 g/dL, P<0.0001), with no difference between captopril and losartan groups (P>0.3). CONCLUSION: Haemoglobin is an independent predictor of mortality in CHF patients, with anaemic and polycythaemic patients having the worst survival... - Heart transplantation in heart failure: the prognostic importance of body mass index at time of surgery and subsequent weight changesAndrew L Clark
Department of Cardiology, Univerity of Hull, and Department of Cardiac Surgery, Royal Brompton Hospital, London, UK
Eur J Heart Fail 9:839-44. 2007..We studied the effect of body mass index (BMI), and the effect of subsequent weight change, on survival following transplantation in 1902 consecutive patients... - The relationship between cholesterol and survival in patients with chronic heart failureMathias Rauchhaus
Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
J Am Coll Cardiol 42:1933-40. 2003..CONCLUSIONS: In patients with CHF, lower serum total cholesterol is independently associated with a worse prognosis... - Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body compositionWolfram Doehner
Division of Applied Cachexia Research, Department of Cardiology, Charite, Campus Virchow Klinikum, Berlin, Germany
Int J Cardiol 138:19-24. 2010..GLUT4, the predominant glucose transporter in the skeletal muscle promotes the rate-limiting step of glucose utilization in skeletal muscle. The significance of skeletal muscle GLUT4 in patients with CHF has not been studied in detail... - The effects of bilateral lung transplantation on ventilatory efficiency, oxygen uptake and the right heart: a two-yr follow-upDirk Habedank
Department of Cardiology, Charite University Medicine Berlin, Campus Virchow, Germany
Clin Transplant 25:E38-45. 2011.... - Anaemia is an independent predictor of death in patients hospitalized for acute heart failureStephan von Haehling
Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
Clin Res Cardiol 99:107-13. 2010..Acute heart failure is associated with a poor prognosis. It is important to identify patients at increased risk of adverse events. The presence of anaemia could help in this regard... - Cardiac cachexia: a systematic overviewStephan von Haehling
Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
Pharmacol Ther 121:227-52. 2009..Other drug classes of interest comprise angiotensin-converting enzyme inhibitors, beta-blockers, anabolic steroids, beta-adrenergic agonists, anti-inflammatory substances, statins, thalidomide, proteasome inhibitors, and pentoxifylline... - Leukocyte redistribution: effects of beta blockers in patients with chronic heart failureStephan von Haehling
Applied Cachexia Research, Dept of Cardiology, Charite Medical School, Campus Virchow Clinic, Berlin, Germany
PLoS ONE 4:e6411. 2009..Here we investigate whether a leukocyte redistribution occurs in CHF and whether this effect is influenced by beta-blocker therapy... - Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemiaStefan D Anker
Department of Cardiology, Charite, Campus Virchow Klinikum, Augustenburger Platz 1, Berlin D 13353, Germany
Eur J Heart Fail 11:1084-91. 2009..gov NCT00520780) was designed to determine the effect of i.v. iron repletion therapy using ferric carboxymaltose on self-reported patient global assessment (PGA) and New York Heart Association (NYHA) in patients with CHF and ID... - The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failureSabine Genth-Zotz
Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
Eur J Heart Fail 8:366-72. 2006..Plasma LPS activity is elevated in patients with severe chronic heart failure (CHF). An anti-CD14 antibody, IC14, blocks TNF production in healthy volunteers. It is not known whether IC14 prevents TNF production in CHF patients... - Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trialDarlington O Okonko
Clinical Cardiology, NHLI, Imperial College London, London, United Kingdom
J Am Coll Cardiol 51:103-12. 2008..We tested the hypothesis that intravenous iron improves exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure (CHF) and iron deficiency... - Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS studyStephan von Haehling
Department of Cardiology, Applied Cachexia Research, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
Eur J Heart Fail 13:656-63. 2011..In addition, we sought to study the effects of nebivolol on the development of anaemia... - Uric acid in chronic heart failureWolfram Doehner
Division of Applied Cachexia Research, Department of Cardiology, Charite Medical School, Humboldt University, D 13353 Berlin, Germany
Semin Nephrol 25:61-6. 2005..In this article, the significance of the xanthine oxidase metabolic pathway in CHF is discussed. Data on xanthine oxidase inhibition are reviewed, which suggest a beneficial effect of therapeutically targeting this enzymatic pathway... - Biomarkers for chronic heart failureMitja Lainscak
Division of Applied Cachexia Research, Department of Cardiology, Campus Virchow Clinic, Charite Universitatsmedizin Berlin, Berlin, Germany
Heart Fail Monit 5:77-82. 2007..Lastly, we anticipate the potential of biomarkers in a variety of chronic diseases with similar pathophysiology... - Hormonal consequences and prognosis of chronic heart failurePhilipp Attanasio
Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
Curr Opin Endocrinol Diabetes Obes 18:224-30. 2011..This review aims to highlight players of the catabolic-anabolic imbalance, regulators or appetite, and other mediators that are involved in the progression of CHF to cachexia... - Exercise hyperventilation in chronic heart failure is not caused by systemic lactic acidosisRoland Wensel
National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London, UK
Eur J Heart Fail 7:1105-11. 2005..Patients with heart failure have an abnormally high ventilatory response to exercise associated with gas exchange defects and reduced arterial pCO(2)... - Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failureWolfram Doehner
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College, London, United Kingdom
J Am Coll Cardiol 46:1019-26. 2005..The aim of this study was to determine the significance of insulin resistance as an independent risk factor for impaired prognosis in patients with chronic heart failure (CHF)... - The cardiac component of cardiac cachexiaViorel G Florea
Department of Cardiac Medicine, National Heart and Lung Institute, London, United Kingdom
Am Heart J 144:45-50. 2002..This study sought to assess the cardiac dimensions, mass, and function and changes in these parameters over time in patients with chronic heart failure with and without cachexia... - Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failureGabor Foldes
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
Int J Cardiol 124:80-5. 2008..Innate immune activation mediated by myocardial Toll-like receptors (TLRs) is involved in cardiovascular disease. The function and role of TLRs on peripheral leukocytes in human chronic heart failure (CHF) are not known... - Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic reviewWolfram Doehner
Center for Stroke Research Berlin, Charite, Berlin, Germany
Wien Klin Wochenschr 121:293-6. 2009..Retrospective and epidemiological data for their beneficial effect in chronic obstructive pulmonary disease begin to accumulate and new fields (e.g. cancer and stroke) could be pending in the future... - Ferric carboxymaltose in patients with heart failure and iron deficiencyStefan D Anker
Department of Cardiology, Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin
N Engl J Med 361:2436-48. 2009.... - The relationship between tumor necrosis factor-?, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failureAmalia Vaz Pérez
Competence Network Heart Failure, Department of Cardiology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Germany
Int J Cardiol 141:39-43. 2010..Brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) are thought to reflect cardiac functional and structural damage... - Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failureTibor Szabo
Applied Cachexia Research, Department of Cardiology, Campus Virchow Klinikum, Charite University Medical School, Berlin, Germany
Int J Cardiol 147:47-51. 2011..Their value and discriminatory power in comparison to dynamic range assessment of Si by minimal modelling are not well established... - Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failureStephan von Haehling
Applied Cachexia Research, Department of Cardiology, Charite Medical School, Berlin, Germany
J Am Coll Cardiol 50:1973-80. 2007..Our aim was assess the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) using a new immunoassay in patients with chronic heart failure (HF)... - Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failureSabine Genth-Zotz
Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
Am J Cardiol 90:1226-30. 2002..These results suggest that elevated plasma endotoxin activity observed in patients with HF is of pathophysiologic relevance... - Anemia in heart failure: an overview of current conceptsStephan von Haehling
Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
Future Cardiol 7:119-29. 2011..Finally, this article describes the potential costs incurred by treating anemic patients with heart failure... - Association of deranged adrenal steroid metabolism with anemia in chronic heart failureDarlington O Okonko
Clinical Cardiology, National Heart and Lung Institute, Imperial College, London, UK
Am J Cardiol 96:101-3. 2005..The cortisol/DHEA ratio was independently and inversely associated with hemoglobin concentrations, suggesting that alterations of the steroid milieu may play a role in the pathogenesis of anemia in CHF... - Role of iron deficiency and anemia in cardio-renal syndromesPhilipp Attanasio
Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
Semin Nephrol 32:57-62. 2012..This article summarizes studies investigating the influence of iron deficiency with or without anemia in chronic kidney disease and CHF and gives an overview of preparations of intravenous iron currently available... - Ghrelin and Its Analogues, BIM-28131 and BIM-28125, Improve Body Weight and Regulate the Expression of MuRF-1 and MAFbx in a Rat Heart Failure ModelSandra Palus
Applied Cachexia Research, Department of Cardiology, Charite Medical School, Berlin, Germany
PLoS ONE 6:e26865. 2011..The GHS-1a-receptor is not only found in the brain, but also in other tissues, including the myocardium. Human clinical trials with native ghrelin in cardiac cachexia demonstrated increases in appetite, weight and cardiac output... - Ursodeoxycholic Acid in patients with chronic heart failure a double-blind, randomized, placebo-controlled, crossover trialStephan von Haehling
Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany Center for Cardiovascular Research CCR, Charite Medical School, Campus Mitte, Berlin, Germany
J Am Coll Cardiol 59:585-92. 2012..This study sought to assess the effects of ursodeoxycholic acid (UDCA) on endothelial function and inflammatory markers in patients with chronic heart failure (CHF)... - Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failureAndreas Krack
Department of Cardiology, Friedrich Schiller University, Erlanger Allee 101, D 07740, Jena, Germany
Eur J Heart Fail 6:403-7. 2004..In CHF inflammatory immune activation is hypothesized to result from a chronic endotoxin challenge due to bacterial translocation of hypoperfused intestinal mucosa... - No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failureYoshihiro J Akashi
Division of Applied Cachexia Research, Department of Cardiology, Charite Medical School, Berlin, Germany
Int J Cardiol 137:267-75. 2009..Ghrelin, was observed to have treatment-potential for severe chronic heart failure (CHF) and cardiac cachexia based on anti-cachectic and cardio-protective effects... - Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS durationPaul R Kalra
Clinical Cardiology, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK
Int J Cardiol 86:225-31. 2002..Heart failure patients with moderate QRS prolongation share similar impairment of exercise capacity and functional class to those with severe prolongation... - Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangementFriedrich Koehler
Department of Cardiology, Charite University Hospital, Campus Mitte, Berlin, Germany
Int J Cardiol 119:83-9. 2007..Anorexia may importantly contribute to weight loss in COPD, however, the association between immune and hormonal derangement and altered appetite has not been studied in detail... - Exercise capacity and body composition in living-donor renal transplant recipients over timeDirk Habedank
Department Cardiology, Applied Cachexia Research, Charite Campus Virchow Klinikum, Berlin, Germany
Nephrol Dial Transplant 24:3854-60. 2009..Renal transplantation (RTx) restitutes the function of the failing organ and induces convalescence of the entire organism. Our study investigates whether this is accompanied by improvements in cardiovascular function and structural changes... - Reversibility of cachexia after bilateral lung transplantationDirk Habedank
Department of Cardiology, Division of Applied Cachexia Research, Charite Campus Virchow Klinikum, Berlin, Germany
Int J Cardiol 133:46-50. 2009.... - The emerging role of the gut in chronic heart failureAnja Sandek
Applied Cachexia Research, Department of Cardiology, Campus Virchow Klinikum, Charite, Berlin, Germany
Curr Opin Clin Nutr Metab Care 11:632-9. 2008..Circulating cytokines act as cardiosuppressors. Their plasma levels predict increased mortality in chronic heart failure... - Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flowWolfram Doehner
Division of Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
Eur Heart J 28:821-8. 2007.... - Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markersMitja Lainscak
Department of Cardiology, Division of Applied Cachexia Research, Campus Virchow Clinic, Charite Universitatsmedizin Berlin, Germany
Int J Cardiol 132:303-11. 2009..Finally, we speculate about the potential of sharing the biomarkers over a variety of chronic diseases with similar pathophysiology... - The gut and intestinal bacteria in chronic heart failureAnja Sandek
Applied Cachexia Research, Department of Cardiology, Campus Virchow Klinikum, Charite Medical School, Augustenburger Platz 1, 13353 Berlin, Germany
Curr Drug Metab 10:22-8. 2009..Therefore, the gut poses an interesting target for therapeutic interventions in patients with CHF... - Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failureStephan von Haehling
Department of Clinical Cardiology, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK
Cardiovasc Res 73:298-309. 2007..Finally, therapeutic approaches are discussed. These include dietary advice, ongoing studies, and future possibilities... - Nutrition in heart failure: an updateAnja Sandek
Applied Cachexia Research, Department of Cardiology, Charite Medical School, Berlin, Germany
Curr Opin Clin Nutr Metab Care 12:384-91. 2009..Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia... - Changes in exercise capacity, ventilation, and body weight following heart transplantationDirk Habedank
Division of Applied Cachexia Research, Department of Cardiology, Charite Campus Virchow Klinikum, Berlin, Germany
Eur J Heart Fail 9:310-6. 2007..Our study prospectively examined changes in these parameters over 24 months following heart transplantation (HTx) and evaluated the potentially confounding effects of weight gain... - Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)Marcus D Flather
Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Trust, London, UK
Eur Heart J 26:215-25. 2005..8%) on nebivolol and 192 (18.1%) on placebo (HR 0.88, 95% CI 0.71-1.08; P=0.21). CONCLUSION: Nebivolol, a beta-blocker with vasodilating properties, is an effective and well-tolerated treatment for heart failure in the elderly... - Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alphaWolfram Doehner
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK
Int J Cardiol 83:73-81. 2002..The purpose of this study was to examine in patients with CHF and in comparison to healthy controls subjects whether norepinephrine, TNFalpha or leptin relate to insulin sensitivity... - Inflammatory biomarkers in heart failure revisited: much more than innocent bystandersStephan von Haehling
Department of Cardiology, Applied Cachexia Research, Charite Medical School, Berlin, Germany
Heart Fail Clin 5:549-60. 2009..In addition to these acute phase reactants, several adhesion molecules, and lipopolysaccharide-signaling pathways are discussed... - Prognosis and therapy approaches of cardiac cachexiaJochen Springer
Division of Applied Cachexia Research, Center for Cardiovascular Research, , Berlin, Germany
Curr Opin Cardiol 21:229-33. 2006..Several interesting treatment options exist, however, which have emerged recently, including appetite stimulants, hormones and 'classical' drugs, such as beta-blockers and ACE inhibitors... - Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failureAidan P Bolger
Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
Am J Cardiol 90:384-9. 2002..IL-10 is, therefore, a potential therapy for use in chronic HF associated with inflammatory immune activation... - Atrial natriuretic peptide and related peptidesYoshihiro J Akashi
Division of Applied Cachexia Research, Center for Cardiovascular Research, Charite Campus Mitte, Berlin, Germany
Clin Chem Lab Med 45:1259-67. 2007..This article summarizes existing data on ANP and related peptides in cardiovascular and other disorders, and outlines the potential clinical usefulness of these markers... - Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studiesWolfram Doehner
Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
Circulation 105:2619-24. 2002..63, P<0.05). CONCLUSIONS: In hyperuricemic CHF patients, XO inhibition with allopurinol improves peripheral vasodilator capacity and blood flow both locally and systemically... - Metabolic and immunologic derangements in cardiac cachexia: where to from here?Sabine Strassburg
Dept. of Cardiology, Applied Cachexia Research, Charit, Campus Virchow-Klinikum, Berlin, Germany
Heart Fail Rev 11:57-64. 2006..Many further investigations are needed to find out more about the pathophysiological pathways, to confirm the previous results, and to evaluate new therapeutics... - Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart diseaseAidan P Bolger
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London, UK
Circulation 106:92-9. 2002.... - Statins and the role of nitric oxide in chronic heart failureStephan von Haehling
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College, School of Medicine, London, UK
Heart Fail Rev 8:99-106. 2003..The doses needed to achieve the desired effects might be much lower than those needed to treat hypercholesterolemia... - Cytokines, apoptosis and cachexia: the potential for TNF antagonismRakesh Sharma
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
Int J Cardiol 85:161-71. 2002..Although this review will concentrate predominantly on the syndrome of CHF, other chronic illnesses such as liver disease, cancer, and sepsis will also be discussed... - Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failureMassimo F Piepoli
Heart Failure Unit, Cardiology, Guglielmo da Saliceto Polichirurgico Hospital, Cantone del Cristo, Piacenza, 29100, Italy
Circulation 114:126-34. 2006.... - How does cachexia influence survival in cancer, heart failure and other chronic diseases?Mitja Lainscak
Division of Applied Cachexia Research, Department of Cardiology, Campus Virchow Clinic, Charite Universitatsmedizin Berlin, Berlin, Germany
Curr Opin Support Palliat Care 1:299-305. 2007..Ultimately, cachexia may develop in 10-15% of patients, who usually perish soon after. We currently have neither a globally accepted definition of cachexia nor any treatment to prevent or treat cachexia... - Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock
Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK
Eur Heart J 29:2641-50. 2008.... - Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implicationsStephan von Haehling
Imperial College School of Medicine, National Heart and Lung Institute, Department of Clinical Cardiology, London, UK
Basic Res Cardiol 99:18-28. 2004..Nevertheless, TNFalpha antagonism remains a major target of CHF therapy, although counterbalancing this cytokine alone may not be sufficient... - Beta-blocker therapy for dynamic left-ventricular outflow tract obstructionFaisal Al-Nasser
Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK
Int J Cardiol 86:199-205. 2002..8+/-0.4 to 1.5+/-0.5 (P<0.0001). CONCLUSIONS: Beta-blockade may represent a beneficial therapeutic approach in selected patients with DLVOTO as identified by stress echocardiography... - Immune and neurohormonal pathways in chronic heart failureRakesh Sharma
Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
Congest Heart Fail 8:23-8, 48. 2002..In the future, it may not be enough to monitor cardiac function alone. Rather, the immune and neurohormonal status of patients may also need to be included in the performance of a complete assessment... - Cachexia in chronic heart failure: prognostic implications and novel therapeutic approachesYoshihiro J Akashi
Division of Applied Cachexia Research, Department of Cardiology, , Augustenburger Platz 1, 13353 Berlin, Germany
Curr Heart Fail Rep 2:198-203. 2005..However, further research will be necessary to identify the exact pathways involved and to find the best therapeutic strategies of using ghrelin to fight the wasting process... - Muscle wasting in cardiac cachexiaSabine Strassburg
Division of Applied Cachexia Research, Department of Cardiology, , Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
Int J Biochem Cell Biol 37:1938-47. 2005..As there is no validated therapy for cardiac cachexia yet, further research is necessary to find more therapeutic options for the wasting process... - Statins: a treatment option for chronic heart failure?Stephan von Haehling
National Heart and Lung Institute, Department of Clinical Cardiology, Imperial College School of Medicine, London, UK
Heart Fail Monit 4:90-7. 2004..It is therefore tempting to speculate that low doses of statins still confer pleiotropic effects without lowering plasma cholesterol levels... - Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertensionChristian F Opitz
Department of Cardiology, DRK Kliniken Berlin Westend, Spandauer Damm 130, 14050 Berlin, Germany
Eur Heart J 26:1895-902. 2005..To describe the long-term clinical efficacy of inhaled iloprost as first-line vasodilator mono-therapy in patients with idiopathic pulmonary arterial hypertension (IPAH)... - Anemia in chronic heart failure--clinical and prognostic significanceT Karhausen
Div. of Applied Cachexia Research, Dept. of Cardiology, Charit, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
Curr Med Chem Cardiovasc Hematol Agents 3:297-303. 2005..The option of therapeutically targeting anemia in CHF is an intriguing novel approach to improve morbidity and potentially mortality in these patients... - The syndrome of cardiac cachexiaStefan D Anker
Franz Volhard Klinik Charité, Campus Berlin Buch at Max Delbrück Centrum for Molecular Medicine, Berlin, Germany
Int J Cardiol 85:51-66. 2002..It is hoped that a better understanding of the pathophysiological mechanisms involved in cardiac cachexia will lead to novel therapeutic strategies in the (near) future... - Future prospects of anticytokine therapy in chronic heart failureStephan von Haehling
Imperial College School of Medicine, Department of Clinical Cardiology, NationalHeart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK
Expert Opin Investig Drugs 14:163-76. 2005.... - Cardiac cachexia in early literature: a review of research prior to MedlineWolfram Doehner
Department of Clinical Cardiology, NHLI, Imperial College School of Medicine, London, UK
Int J Cardiol 85:7-14. 2002..This review presents an overview of early thoughts and milestone studies on metabolic abnormalities and cachexia in chronic heart failure... - Overview of emerging pharmacotherapy in chronic heart failureTibor Szabo
Charite Medical School, Campus Virchow Klinikum, Applied Cachexia Research, Department of Cardiology, Augustenburger Platz 1, 13353 Berlin, Germany
Expert Opin Pharmacother 10:2055-74. 2009..This review will focus on recent developments and potential future candidates of pharmacological CHF therapy... - Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexiaGerasimos S Filippatos
Second Department of Cardiology, Evangelismos General Hospital, 28 Doukissis Plakentias street, 115 23, Athens, Greece
Int J Cardiol 90:107-13. 2003.... - Uric acid as a prognostic marker in acute heart failure--new expectations from an old moleculeWolfram Doehner
Eur J Heart Fail 9:437-9. 2007 - Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trialFranz Hartmann
Medizinische Klinik II, Universitaetsklinikum Schleswig Holstein, Campus Luebeck, Ratzeburger Allee 160, D 23538 Luebeck, Germany
Circulation 110:1780-6. 2004.... - Prognostic utility of growth differentiation factor-15 in patients with chronic heart failureTibor Kempf
Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
J Am Coll Cardiol 50:1054-60. 2007..We explored the prognostic utility of growth differentiation factor (GDF)-15 in patients with chronic heart failure (CHF)... - Pleiotropic effects of angiotensin-converting enzyme inhibitors and the future of cachexia therapyStephan von Haehling
J Am Geriatr Soc 53:2030-1. 2005 - Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testingRoland Wensel
Department of Cardiothoracic Surgery, Deutsches Herzzentrum Berlin, Germany
Circulation 106:319-24. 2002..Prognostic assessment is an important factor in determining medical treatment and lung transplantation. Whether cardiopulmonary exercise testing data predict survival has not been reported previously... - Selective intestinal decontamination in advanced chronic heart failure: a pilot trialViviane M Conraads
Department of Cardiology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium
Eur J Heart Fail 6:483-91. 2004.... - Pathophysiology of peripheral muscle wasting in cardiac cachexiaGerasimos S Filippatos
2nd University Department of Cardiology, Atticon University Hospital, Athens, Greece
Curr Opin Clin Nutr Metab Care 8:249-54. 2005..This manuscript looks at current developments concerning the pathophysiology of skeletal muscle wasting in cardiac cachexia... - Activation of the NF-kappaB system in peripheral blood leukocytes from patients with chronic heart failureEwa A Jankowska
Cardiology Department, Military Hospital, ul Weigla 5, 50 981 Wroclaw, Poland
Eur J Heart Fail 7:984-90. 2005..In vitro experiments were used to elucidate the role of lipopolysaccharide (LPS) as a stimulus for the NF-kappaB system in PBL... - Excessive ventilation during early phase of exercise: a new predictor of poor long-term outcome in patients with chronic heart failureEwa A Jankowska
Cardiology Department, Military Hospital, Weigla 5, 50 981 Wroclaw, Poland
Eur J Heart Fail 9:1024-31. 2007..Whether ventilatory response to early phase of exercise is useful for risk stratification in CHF is unknown... - Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot studyMitja Lainscak
General Hospital Murska Sobota, Internal Medicine Department, Dr Vrbnjaka 6 SI 9000, Murska Sobota, Slovenia
Int J Cardiol 106:319-22. 2006..Cachexia is an independent risk factor for mortality in chronic heart failure (CHF). Beta blockers can reduce body energy expenditure and improve efficiency of substrate utilization... - Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissueMariantonietta Cicoira
Divisione Clinicizzata di Cardiologia, , Italy
J Card Fail 10:421-6. 2004..03). CONCLUSION: Adjustment for lean tissue instead for body weight increases the prognostic power of pVO2, particularly in patients with mild heart failure... - Impact of neurohormonal blockade on association between body mass index and mortalityLinn M A Kennedy
Department of Cardiology, Malmo University Hospital, Lund University, Malmo, Sweden
Int J Cardiol 119:33-40. 2007..The prognostic impact of body mass index (BMI) in patients following acute myocardial infarction (AMI) may be altered by neurohormonal blockade... - Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling patternFaisal Al-Nasser
Clinical Cardiology Department, Royal Brompton Hospital, London, United Kingdom
Am J Cardiol 91:1281-3. 2003 - Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survivalEwa A Jankowska
Cardiology Department, Military Hospital, ul Weigla 5, 50 981 Wroclaw, Poland
Circulation 114:1829-37. 2006.... - Uric acid in CHF: marker or player in a metabolic disease?Wolfram Doehner
Int J Cardiol 115:156-8. 2007